ID   BRAF_HUMAN              Reviewed;         766 AA.
AC   P15056; A4D1T4; Q13878; Q3MIN6; Q9UDP8; Q9Y6T3;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 4.
DT   02-NOV-2010, entry version 141.
DE   RecName: Full=Serine/threonine-protein kinase B-raf;
DE            EC=2.7.11.1;
DE   AltName: Full=Proto-oncogene B-Raf;
DE   AltName: Full=p94;
DE   AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1;
GN   Name=BRAF; Synonyms=BRAF1, RAFB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND
RP   PHOSPHORYLATION AT THR-373.
RC   TISSUE=Testis;
RX   MEDLINE=92375040; PubMed=1508179;
RA   Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R.,
RA   Morrison D.K.;
RT   "95-kilodalton B-Raf serine/threonine kinase: identification of the
RT   protein and its major autophosphorylation site.";
RL   Mol. Cell. Biol. 12:3733-3742(1992).
RN   [2]
RP   SEQUENCE REVISION TO 31-33.
RA   Albert S., Wixler L., Rapp U.R.;
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22616434; PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22737999; PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200.
RC   TISSUE=Placenta;
RX   MEDLINE=92334878; PubMed=1630826;
RA   Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.;
RT   "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci:
RT   B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed
RT   pseudogene.";
RL   Oncogene 7:1657-1660(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354;
RP   361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698;
RP   702-719; 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399;
RP   THR-401 AND SER-729, AND MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 117-766.
RC   TISSUE=Testis;
RX   MEDLINE=91133728; PubMed=2284096;
RA   Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.;
RT   "Complete coding sequence of a human B-raf cDNA and detection of B-raf
RT   protein kinase with isozyme specific antibodies.";
RL   Oncogene 5:1775-1780(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 439-766.
RX   MEDLINE=88302178; PubMed=3043188;
RA   Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.;
RT   "B-raf, a new member of the raf family, is activated by DNA
RT   rearrangement.";
RL   Mol. Cell. Biol. 8:2651-2654(1988).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401 AND SER-729, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-419, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401;
RP   SER-419; SER-446; SER-729 AND SER-750, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-373, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447
RP   AND SER-729, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401 AND SER-729, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-419, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-465 AND SER-614, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-418, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [22]
RP   VARIANTS LUNG CANCER VAL-466 AND ARG-597.
RX   MEDLINE=22349173; PubMed=12460919;
RA   Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.;
RT   "Missense mutations of the BRAF gene in human lung adenocarcinoma.";
RL   Cancer Res. 62:7001-7003(2002).
RN   [23]
RP   VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469;
RP   GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND
RP   ASP-600, AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469;
RP   VAL-597 AND GLU-600.
RX   MEDLINE=22082291; PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J., Hargrave D., Pritchard-Jones K., Maitland N.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RN   [24]
RP   VARIANTS COLORECTAL CANCER ILE-462; SER-463; GLU-464; GLU-600 AND
RP   GLU-601.
RX   MEDLINE=22187000; PubMed=12198537; DOI=10.1038/418934a;
RA   Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B.,
RA   Velculescu V.E.;
RT   "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.";
RL   Nature 418:934-934(2002).
RN   [25]
RP   VARIANTS NHL ALA-469; ARG-469 AND GLY-594.
RX   MEDLINE=22973595; PubMed=14612909; DOI=10.1038/sj.bjc.6601371;
RA   Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y.,
RA   Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.;
RT   "BRAF mutations in non-Hodgkin's lymphoma.";
RL   Br. J. Cancer 89:1958-1960(2003).
RN   [26]
RP   CHARACTERIZATION OF VARIANT MELANOMA GLU-600.
RX   MEDLINE=22861930; PubMed=14500344;
RA   Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M.,
RA   Tuveson D.A.;
RT   "Suppression of BRAF(V599E) in human melanoma abrogates
RT   transformation.";
RL   Cancer Res. 63:5198-5202(2003).
RN   [27]
RP   VARIANTS CFC SYNDROME PRO-246; ARG-257; GLU-469; PHE-485; GLU-499;
RP   LYS-501; GLY-501 AND ASP-581.
RX   PubMed=16474404; DOI=10.1038/ng1749;
RA   Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A.,
RA   Okamoto N., Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D.,
RA   Kavamura M.I., Kurosawa K., Ohashi H., Wilson L., Heron D.,
RA   Bonneau D., Corona G., Kaname T., Naritomi K., Baumann C.,
RA   Matsumoto N., Kato K., Kure S., Matsubara Y.;
RT   "Germline KRAS and BRAF mutations in cardio-facio-cutaneous
RT   syndrome.";
RL   Nat. Genet. 38:294-296(2006).
RN   [28]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-600.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [29]
RP   VARIANTS CFC SYNDROME ARG-257; ALA-467; SER-468; GLU-469; PHE-485;
RP   GLU-499; LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596.
RX   PubMed=16439621; DOI=10.1126/science.1124642;
RA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,
RA   Cruz M.S., McCormick F., Rauen K.A.;
RT   "Germline mutations in genes within the MAPK pathway cause cardio-
RT   facio-cutaneous syndrome.";
RL   Science 311:1287-1290(2006).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581;
RP   ARG-596; ARG-597; VAL-597; GLU-600; GLU-600 AND GLU-600.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [31]
RP   VARIANTS ARG-241; MET-241; PRO-241; CYS-531 AND VAL-597, AND VARIANTS
RP   CFC SYNDROME PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485;
RP   ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND
RP   ARG-709.
RX   PubMed=19206169; DOI=10.1002/humu.20955;
RA   Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C.,
RA   Pantaleoni F., Scioletti A.P., Esposito G., Cordeddu V., Lepri F.,
RA   Petrangeli V., Dentici M.L., Mancini G.M., Selicorni A., Rossi C.,
RA   Mazzanti L., Marino B., Ferrero G.B., Silengo M.C., Memo L.,
RA   Stanzial F., Faravelli F., Stuppia L., Puxeddu E., Gelb B.D.,
RA   Dallapiccola B., Tartaglia M.;
RT   "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous
RT   syndromes: molecular diversity and associated phenotypic spectrum.";
RL   Hum. Mutat. 30:695-702(2009).
CC   -!- FUNCTION: Involved in the transduction of mitogenic signals from
CC       the cell membrane to the nucleus. May play a role in the
CC       postsynaptic responses of hippocampal neuron.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Binds 2 zinc ions per subunit (By similarity).
CC   -!- SUBUNIT: Interacts with RIT1 (By similarity).
CC   -!- INTERACTION:
CC       P04049:RAF1; NbExp=9; IntAct=EBI-365980, EBI-365996;
CC       P31946:YWHAB; NbExp=1; IntAct=EBI-365980, EBI-359815;
CC       P61981:YWHAG; NbExp=1; IntAct=EBI-365980, EBI-359832;
CC       P27348:YWHAQ; NbExp=1; IntAct=EBI-365980, EBI-359854;
CC       P63104:YWHAZ; NbExp=1; IntAct=EBI-365980, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Brain and testis.
CC   -!- DISEASE: Defects in BRAF are a cause of cardiofaciocutaneous
CC       syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-
CC       cutaneous syndrome. CFC syndrome is characterized by a distinctive
CC       facial appearance, heart defects and mental retardation. Heart
CC       defects include pulmonic stenosis, atrial septal defects and
CC       hypertrophic cardiomyopathy. Some affected individuals present
CC       with ectodermal abnormalities such as sparse, friable hair,
CC       hyperkeratotic skin lesions and a generalized ichthyosis-like
CC       condition. Typical facial features are similar to Noonan syndrome.
CC       They include high forehead with bitemporal constriction,
CC       hypoplastic supraorbital ridges, downslanting palpebral fissures,
CC       a depressed nasal bridge, and posteriorly angulated ears with
CC       prominent helices. The inheritance of CFC syndrome is autosomal
CC       dominant.
CC   -!- DISEASE: Note=Defects in BRAF are found in a wide range of
CC       cancers. They are also found in patients with developmental
CC       disorders such as Noonan and LEOPARD syndromes that have
CC       overlapping features with cardiofaciocutaneous syndrome.
CC   -!- DISEASE: Defects in BRAF are involved in lung cancer [MIM:211980].
CC   -!- DISEASE: Defects in BRAF are involved in non-Hodgkin lymphoma
CC       (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the
CC       lymph system, which is part of the body's immune system. NHLs can
CC       occur at any age and are often marked by enlarged lymph nodes,
CC       fever and weight loss.
CC   -!- DISEASE: Defects in BRAF may be a cause of colorectal cancer (CRC)
CC       [MIM:114500].
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. RAF subfamily.
CC   -!- SIMILARITY: Contains 1 phorbol-ester/DAG-type zinc finger.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 RBD (Ras-binding) domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD43193.1; Type=Erroneous gene model prediction;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BRAFID828.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/BRAF";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M95712; AAA35609.2; -; mRNA.
DR   EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; EU600171; ACD11489.1; -; Genomic_DNA.
DR   EMBL; AC006347; AAD15551.1; -; Genomic_DNA.
DR   EMBL; CH236950; EAL24023.1; -; Genomic_DNA.
DR   EMBL; BC101757; AAI01758.1; -; mRNA.
DR   EMBL; BC112079; AAI12080.1; -; mRNA.
DR   EMBL; X65187; CAA46301.1; -; Genomic_DNA.
DR   EMBL; M21001; AAA96495.1; -; mRNA.
DR   IPI; IPI00303797; -.
DR   PIR; A57977; TVHUBF.
DR   RefSeq; NP_004324.2; -.
DR   UniGene; Hs.550061; -.
DR   PDB; 1UWH; X-ray; 2.95 A; A/B=448-723.
DR   PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723.
DR   PDB; 2FB8; X-ray; 2.90 A; A/B=445-723.
DR   PDB; 2L05; NMR; -; A=149-232.
DR   PDB; 3C4C; X-ray; 2.57 A; A/B=444-719.
DR   PDB; 3C4D; X-ray; 2.65 A; A/B=444-719.
DR   PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726.
DR   PDB; 3IDP; X-ray; 2.70 A; A/B=434-727.
DR   PDB; 3II5; X-ray; 2.79 A; A/B=432-726.
DR   PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237.
DR   PDBsum; 1UWH; -.
DR   PDBsum; 1UWJ; -.
DR   PDBsum; 2FB8; -.
DR   PDBsum; 2L05; -.
DR   PDBsum; 3C4C; -.
DR   PDBsum; 3C4D; -.
DR   PDBsum; 3D4Q; -.
DR   PDBsum; 3IDP; -.
DR   PDBsum; 3II5; -.
DR   PDBsum; 3NY5; -.
DR   ProteinModelPortal; P15056; -.
DR   SMR; P15056; 157-227, 232-283.
DR   DIP; DIP-1045N; -.
DR   IntAct; P15056; 52.
DR   MINT; MINT-1574728; -.
DR   STRING; P15056; -.
DR   PhosphoSite; P15056; -.
DR   PRIDE; P15056; -.
DR   Ensembl; ENST00000288602; ENSP00000288602; ENSG00000157764.
DR   GeneID; 673; -.
DR   KEGG; hsa:673; -.
DR   UCSC; uc003vwc.2; human.
DR   CTD; 673; -.
DR   GeneCards; GC07M140424; -.
DR   H-InvDB; HIX0007148; -.
DR   HGNC; HGNC:1097; BRAF.
DR   HPA; CAB004552; -.
DR   HPA; HPA001328; -.
DR   MIM; 114500; phenotype.
DR   MIM; 115150; phenotype.
DR   MIM; 164757; gene.
DR   MIM; 211980; phenotype.
DR   MIM; 605027; phenotype.
DR   Orphanet; 1340; Cardiofaciocutaneous syndrome.
DR   Orphanet; 500; LEOPARD syndrome.
DR   PharmGKB; PA25408; -.
DR   HOGENOM; HBG506535; -.
DR   HOVERGEN; HBG001886; -.
DR   InParanoid; P15056; -.
DR   OMA; MKRLMAD; -.
DR   OrthoDB; EOG9QC3QR; -.
DR   PhylomeDB; P15056; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; cd8tcrdownstreampathway; Downstream signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; tcrraspathway; Ras signaling in the CD4+ TCR pathway.
DR   Pathway_Interaction_DB; mapktrkpathway; Trk receptor signaling mediated by the MAPK pathway.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   DrugBank; DB00398; Sorafenib.
DR   NextBio; 2776; -.
DR   PMAP-CutDB; P15056; -.
DR   ArrayExpress; P15056; -.
DR   Bgee; P15056; -.
DR   CleanEx; HS_BRAF; -.
DR   Genevestigator; P15056; -.
DR   GermOnline; ENSG00000157764; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006916; P:anti-apoptosis; TAS:ProtInc.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; EXP:Reactome.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; Prot_Kinase_C-like_PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR003116; Raf-like_ras-bd.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF02196; RBD; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00455; RBD; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50898; RBD; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cardiomyopathy;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Kinase; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    766       Serine/threonine-protein kinase B-raf.
FT                                /FTId=PRO_0000085665.
FT   DOMAIN      155    227       RBD.
FT   DOMAIN      457    717       Protein kinase.
FT   ZN_FING     234    280       Phorbol-ester/DAG-type.
FT   NP_BIND     463    471       ATP (By similarity).
FT   COMPBIAS      6     11       Poly-Gly.
FT   COMPBIAS    122    129       Poly-Ser.
FT   COMPBIAS    428    432       Poly-Ser.
FT   ACT_SITE    576    576       Proton acceptor (By similarity).
FT   METAL       235    235       Zinc 1 (By similarity).
FT   METAL       248    248       Zinc 2 (By similarity).
FT   METAL       251    251       Zinc 2 (By similarity).
FT   METAL       261    261       Zinc 1 (By similarity).
FT   METAL       264    264       Zinc 1 (By similarity).
FT   METAL       269    269       Zinc 2 (By similarity).
FT   METAL       272    272       Zinc 2 (By similarity).
FT   METAL       280    280       Zinc 1 (By similarity).
FT   BINDING     483    483       ATP (By similarity).
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES     151    151       Phosphoserine.
FT   MOD_RES     365    365       Phosphoserine.
FT   MOD_RES     373    373       Phosphothreonine; by autocatalysis.
FT   MOD_RES     396    396       Phosphothreonine.
FT   MOD_RES     399    399       Phosphoserine.
FT   MOD_RES     401    401       Phosphothreonine.
FT   MOD_RES     418    418       N6-acetyllysine.
FT   MOD_RES     419    419       Phosphoserine.
FT   MOD_RES     446    446       Phosphoserine.
FT   MOD_RES     447    447       Phosphoserine.
FT   MOD_RES     465    465       Phosphoserine.
FT   MOD_RES     614    614       Phosphoserine.
FT   MOD_RES     729    729       Phosphoserine.
FT   MOD_RES     750    750       Phosphoserine.
FT   VARIANT     241    241       T -> M (in a patient with Noonan
FT                                syndrome).
FT                                /FTId=VAR_058620.
FT   VARIANT     241    241       T -> P (in a patient with LEOPARD
FT                                syndrome).
FT                                /FTId=VAR_058621.
FT   VARIANT     241    241       T -> R (in a patient with Noonan
FT                                syndrome).
FT                                /FTId=VAR_058622.
FT   VARIANT     245    245       L -> F (in CFC syndrome).
FT                                /FTId=VAR_058623.
FT   VARIANT     246    246       A -> P (in CFC syndrome).
FT                                /FTId=VAR_026113.
FT   VARIANT     257    257       Q -> R (in CFC syndrome).
FT                                /FTId=VAR_026114.
FT   VARIANT     275    275       E -> K (in CFC syndrome).
FT                                /FTId=VAR_058624.
FT   VARIANT     301    301       P -> S (in dbSNP:rs34776339).
FT                                /FTId=VAR_040391.
FT   VARIANT     462    462       R -> I (in colorectal cancer).
FT                                /FTId=VAR_018613.
FT   VARIANT     463    463       I -> S (in colorectal cancer).
FT                                /FTId=VAR_018614.
FT   VARIANT     464    464       G -> E (in colorectal cancer).
FT                                /FTId=VAR_018615.
FT   VARIANT     464    464       G -> V (in a colorectal cancer cell line;
FT                                elevated kinase activity; efficiently
FT                                induces cell transformation).
FT                                /FTId=VAR_018616.
FT   VARIANT     466    466       G -> A (in melanoma).
FT                                /FTId=VAR_018617.
FT   VARIANT     466    466       G -> E (in melanoma).
FT                                /FTId=VAR_018618.
FT   VARIANT     466    466       G -> V (in lung cancer).
FT                                /FTId=VAR_018512.
FT   VARIANT     467    467       S -> A (in CFC syndrome).
FT                                /FTId=VAR_035096.
FT   VARIANT     468    468       F -> S (in CFC syndrome).
FT                                /FTId=VAR_035097.
FT   VARIANT     469    469       G -> A (in NHL; also in a lung
FT                                adenocarcinoma sample; somatic mutation;
FT                                elevated kinase activity; efficiently
FT                                induces cell transformation).
FT                                /FTId=VAR_018620.
FT   VARIANT     469    469       G -> E (in CFC syndrome and colon
FT                                cancer).
FT                                /FTId=VAR_018621.
FT   VARIANT     469    469       G -> R (in NHL).
FT                                /FTId=VAR_018622.
FT   VARIANT     469    469       G -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040392.
FT   VARIANT     485    485       L -> F (in CFC syndrome).
FT                                /FTId=VAR_026115.
FT   VARIANT     499    499       K -> E (in CFC syndrome).
FT                                /FTId=VAR_026116.
FT   VARIANT     499    499       K -> N (in CFC syndrome).
FT                                /FTId=VAR_058625.
FT   VARIANT     501    501       E -> G (in CFC syndrome).
FT                                /FTId=VAR_026117.
FT   VARIANT     501    501       E -> K (in CFC syndrome).
FT                                /FTId=VAR_026118.
FT   VARIANT     525    525       L -> P (in CFC syndrome).
FT                                /FTId=VAR_058626.
FT   VARIANT     531    531       W -> C (in a patient with Noonan
FT                                syndrome).
FT                                /FTId=VAR_058627.
FT   VARIANT     581    581       N -> D (in CFC syndrome).
FT                                /FTId=VAR_026119.
FT   VARIANT     581    581       N -> S (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040393.
FT   VARIANT     586    586       E -> K (in ovarian cancer).
FT                                /FTId=VAR_018623.
FT   VARIANT     594    594       D -> G (in NHL).
FT                                /FTId=VAR_018624.
FT   VARIANT     595    595       F -> L (in colon cancer and CFC
FT                                syndrome).
FT                                /FTId=VAR_018625.
FT   VARIANT     596    596       G -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_018626.
FT   VARIANT     596    596       G -> V (in CFC syndrome).
FT                                /FTId=VAR_035098.
FT   VARIANT     597    597       L -> R (in lung cancer and ovarian
FT                                cancer; ovarian serous carcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_018513.
FT   VARIANT     597    597       L -> V (in a patient with Noonan
FT                                syndrome; also in a lung adenocarcinoma
FT                                sample; somatic mutation; elevated kinase
FT                                activity; efficiently induces cell
FT                                transformation).
FT                                /FTId=VAR_018627.
FT   VARIANT     599    599       T -> R (in CFC syndrome).
FT                                /FTId=VAR_058628.
FT   VARIANT     600    600       V -> D (in a melanoma cell line; requires
FT                                2 nucleotide substitutions).
FT                                /FTId=VAR_018628.
FT   VARIANT     600    600       V -> E (in sarcoma, colorectal
FT                                adenocarcinoma, metastatic melanoma,
FT                                ovarian serous carcinoma; somatic
FT                                mutation; most common mutation; elevated
FT                                kinase activity; efficiently induces cell
FT                                transformation; suppression of mutation
FT                                in melanoma causes growth arrest and
FT                                promotes apoptosis).
FT                                /FTId=VAR_018629.
FT   VARIANT     601    601       K -> E (in colorectal cancer).
FT                                /FTId=VAR_018630.
FT   VARIANT     601    601       K -> Q (in CFC syndrome).
FT                                /FTId=VAR_058629.
FT   VARIANT     638    638       D -> E (in CFC syndrome).
FT                                /FTId=VAR_058630.
FT   VARIANT     709    709       Q -> R (in CFC syndrome).
FT                                /FTId=VAR_058631.
FT   CONFLICT    766    766       H -> D (in Ref. 10; AAA96495).
FT   STRAND      461    465
FT   STRAND      470    484
FT   HELIX       494    505
FT   STRAND      516    520
FT   STRAND      522    524
FT   STRAND      526    530
FT   STRAND      534    536
FT   HELIX       537    542
FT   HELIX       550    569
FT   HELIX       579    581
FT   STRAND      582    585
FT   STRAND      588    592
FT   HELIX       617    619
FT   HELIX       622    625
FT   HELIX       635    651
FT   TURN        655    658
FT   HELIX       662    670
FT   HELIX       678    680
FT   HELIX       687    696
FT   HELIX       701    703
FT   HELIX       707    719
SQ   SEQUENCE   766 AA;  84437 MW;  0798C2AAB487E813 CRC64;
     MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH
     IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV
     TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS
     LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK
     TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI
     PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR
     DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP
     GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV
     AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH
     LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV
     KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN
     NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS
     LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH
//
